Processa Pharmaceuticals (PCSA) Proxy Filing summary

Executive summary

• Special Meeting called to vote on four key proposals: increasing authorized shares, a reverse stock split, amending the 2019 Omnibus Incentive Plan, and potential adjournment to solicit more proxies if needed.

• Board unanimously recommends approval of all proposals to provide flexibility for future capital needs and maintain Nasdaq listing.

• Proposals aim to support future financing, compliance with listing standards, and competitive employee compensation.

Voting matters and shareholder proposals

• Proposals include: (1) increasing authorized common stock, (2) reverse stock split at a ratio to be determined by the Board, (3) amending the 2019 Omnibus Incentive Plan to increase available shares, and (4) adjournment if more proxies are needed.

• Each proposal requires a majority of votes cast for approval; abstentions and broker non-votes have no effect.

• Board and management do not intend to present other business at the meeting.

Shareholder rights and capital structure

• Proposal to increase authorized common stock from 100,000,000 to a higher number to provide flexibility for future equity offerings and business opportunities.

• Reverse stock split proposal aims to increase per-share price to maintain Nasdaq listing and appeal to a broader investor base.

• No immediate plans to issue additional shares, but Board wants flexibility for future needs.

• No preemptive rights for existing shareholders; potential for future dilution if new shares are issued.